ESR1 and breast carcinoma: We further tested a panel of six human breast cancer cells lines either expressing estrogen receptor (ER+) (ZR75.1, T47D and MCF7) or not (ER-, without amplification of the HER2 oncogene) (BT549, Cal51, MDAMB231), for their cell-death response to this treatment (Figure 1B).